Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials

por Hughes, Derralynn A, Gonzalez, Derlis E, Lukina, Elena A, Mehta, Atul, Kabra, Madhulika, Elstein, Deborah, Kisinovsky, Isaac, Giraldo, Pilar, Bavdekar, Ashish, Hangartner, Thomas N, Wang, Nan, Crombez, Eric, Zimran, Ari
Publicado 2015

Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab

por Kulagin, Alexander D., Ptushkin, Vadim V., Lukina, Elena A., Davydkin, Igor L., Korobkin, Alexander V., Shamrai, Vladimir S., Konstantinova, Tatyana S., Kaporskaya, Tatyana S., Mitina, Tatyana A., Ksenzova, Tatyana I., Zuev, Evgeny V., Markova, Oksana A., Gapchenko, Elena V., Kudlay, Dmitry A.
Publicado 2021

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative

por Mehta, Atul, Kuter, David J., Salek, Sam S., Belmatoug, Nadia, Bembi, Bruno, Bright, Jeremy, vom Dahl, Stephan, Deodato, Federica, Di Rocco, Maja, Göker‐Alpan, Ozlem, Hughes, Derralynn A., Lukina, Elena A., Machaczka, Maciej, Mengel, Eugen, Nagral, Aabha, Nakamura, Kimitoshi, Narita, Aya, Oliveri, Beatriz, Pastores, Gregory, Pérez‐López, Jordi, Ramaswami, Uma, Schwartz, Ida V., Szer, Jeff, Weinreb, Neal J., Zimran, Ari
Publicado 2019